Description:
Tuberculosis (TB) has been identified as one of the most highly infectious diseases in the world. Tuberculosis can be identified as pulmonary or extrapulmonary. Therapy for TB is a combination of several drugs in one treatment. The effectiveness and toxicity of TB therapy may differ in each patient because of some risk factors, especially genetic variations. This review describes several genes that can affect the effectiveness and toxicity of antituberculosis drugs, namely UGT1A1, SLCO1B1, NAT2, and CYP2E1. This review was conducted utilizing the PubMed database, with keywords used as follows: polymorphism, antituberculosis, and tuberculosis. The presence of polymorphisms in these genes can result in hepatotoxicity and decreased drug bioavailability. Therefore, polymorphisms in these genes can determine the effectiveness of TB therapy.

URL:
http://103.158.96.210:88/web_repository/uploads/editorijap,+39540-Article+Text-186367-1-6-20201012.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
GITA WIDI SETYOWATI